Company intelligence / Profile preview
ValiRx plc
Nuneaton, England, United Kingdomvalirx.com ↗
- Ownership
- Private
- Employees
- ~8
- Development stage
- Preclinical
01
Overview
The company has completed Phase I/II trials for VAL201 for prostate cancer treatment and Phase II clinical trial for VAL401 for end-stage non-small cell lung cancer treatment. Other programs are in pre-clinical development.
- Therapeutic areas
- Women's HealthOncologyInfectious Diseases
- Modalities
- PeptidesReformulated drugsPeptide nanoparticle formulations
- Industry
- Biotech
02
Drug pipeline
6 assets5 more assets in the full pipeline.
Request access →03
Partnerships
ValiSeek (joint venture with Tangent Reprofiling Ltd)Screenin3d LimitedUniversity of Dundee and its Drug Discovery UnitSTINGRAY BIO
Beyond the preview
Go deeper on ValiRx plc.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Full profile accessExplore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Full profile accessTrace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Full profile accessCompare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Full profile accessExplore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Full profile accessConnect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on ValiRx plc.